RxDoctor Payments Data

Ivan Castano, MD

Family Medicine · Hialeah, FLNPI 1649299652

Payments from drug & device makers

$15,519in general payments, 2019–2025

Across 126 payments — averaging $123.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$13K
  • Sanofi-aventis U.S. LLC$376
  • Amarin Pharma, Inc.$249
  • Novartis$212
  • AbbVie$206
  • Novo Nordisk$204
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$2,62399%
  • Education$301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,519 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$25,823
Medicare patients
25
Services billed
252

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol38$57,168
EliquisApixaban23$38,532
OzempicSemaglutide24$31,582
MounjaroTirzepatide26$31,479
EntrestoSacubitril/Valsartan15$27,835
XareltoRivaroxaban16$15,083
VascepaIcosapent Ethyl18$11,932
Stiolto RespimatTiotropium Br/Olodaterol Hcl15$8,391
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$7,303
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$2,872
SynthroidLevothyroxine Sodium23$2,074
Omeprazole58$1,363
Telmisartan30$1,158
Ventolin HfaAlbuterol Sulfate13$955
Memantine Hcl ErMemantine Hcl11$945

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$13,227$64,47149 claims
Novo NordiskOzempic$204$31,58224 claims
Lilly USA, LLCMounjaro$133$31,47926 claims
NovartisEntresto$212$27,83515 claims
Johnson & JohnsonXarelto$123$15,08316 claims
Boehringer IngelheimStiolto Respimat$56$8,39115 claims
AbbVieSynthroid$206$2,07423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Hialeah

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →